Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Raised to $850.00

Regeneron Pharmaceuticals (NASDAQ:REGN) had its price objective boosted by BMO Capital Markets from $725.00 to $850.00 in a research note published on Thursday,Benzinga reports. They currently have an outperform rating on the biopharmaceutical company’s stock.

REGN has been the subject of several other research reports. UBS Group increased their price target on shares of Regeneron Pharmaceuticals from $595.00 to $660.00 and gave the stock a “neutral” rating in a research report on Friday, November 7th. Bank of America upped their price objective on Regeneron Pharmaceuticals from $543.00 to $627.00 and gave the company an “underperform” rating in a research note on Wednesday, October 29th. Wall Street Zen raised Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Monday, November 17th. Morgan Stanley lowered Regeneron Pharmaceuticals from an “overweight” rating to an “equal weight” rating and set a $767.00 price target on the stock. in a research note on Wednesday. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a research report on Monday, December 1st. Three research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating, nine have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Regeneron Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $777.36.

Regeneron Pharmaceuticals Stock Down 0.6%

Shares of REGN stock opened at $718.36 on Thursday. Regeneron Pharmaceuticals has a one year low of $476.49 and a one year high of $800.99. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.06 and a quick ratio of 3.33. The stock has a fifty day moving average price of $650.69 and a 200 day moving average price of $588.35. The stock has a market cap of $75.50 billion, a P/E ratio of 17.20, a price-to-earnings-growth ratio of 2.06 and a beta of 0.37.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Tuesday, October 28th. The biopharmaceutical company reported $11.83 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $9.73 by $2.10. The company had revenue of $3.75 billion during the quarter, compared to analysts’ expectations of $3.57 billion. Regeneron Pharmaceuticals had a net margin of 32.13% and a return on equity of 13.76%. The business’s revenue was up .9% on a year-over-year basis. During the same quarter in the prior year, the company posted $12.46 EPS. Analysts predict that Regeneron Pharmaceuticals will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Friday, December 5th. Shareholders of record on Thursday, November 20th were given a $0.88 dividend. The ex-dividend date was Thursday, November 20th. This represents a $3.52 annualized dividend and a yield of 0.5%. Regeneron Pharmaceuticals’s payout ratio is presently 8.43%.

Insiders Place Their Bets

In related news, Director Christine A. Poon sold 6,500 shares of the company’s stock in a transaction dated Wednesday, October 29th. The shares were sold at an average price of $654.27, for a total transaction of $4,252,755.00. Following the transaction, the director owned 2,352 shares in the company, valued at $1,538,843.04. This represents a 73.43% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Jason Pitofsky sold 431 shares of the stock in a transaction dated Friday, November 7th. The stock was sold at an average price of $651.43, for a total transaction of $280,766.33. Following the sale, the vice president directly owned 4,233 shares in the company, valued at approximately $2,757,503.19. This represents a 9.24% decrease in their position. The disclosure for this sale is available in the SEC filing. 7.02% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

Large investors have recently modified their holdings of the stock. Brighton Jones LLC lifted its holdings in Regeneron Pharmaceuticals by 261.8% during the 4th quarter. Brighton Jones LLC now owns 948 shares of the biopharmaceutical company’s stock worth $675,000 after buying an additional 686 shares in the last quarter. Arkadios Wealth Advisors acquired a new stake in shares of Regeneron Pharmaceuticals in the 1st quarter valued at $259,000. Blair William & Co. IL raised its position in shares of Regeneron Pharmaceuticals by 2.2% during the first quarter. Blair William & Co. IL now owns 1,282 shares of the biopharmaceutical company’s stock worth $813,000 after acquiring an additional 27 shares during the last quarter. Thoroughbred Financial Services LLC lifted its stake in shares of Regeneron Pharmaceuticals by 14.9% during the first quarter. Thoroughbred Financial Services LLC now owns 680 shares of the biopharmaceutical company’s stock valued at $431,000 after acquiring an additional 88 shares during the period. Finally, Costello Asset Management INC acquired a new position in shares of Regeneron Pharmaceuticals during the first quarter valued at $27,000. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.